FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
What happened
FDA reviewed the company's website, https://tryamie.com, in March 2026 and found it offers compounded semaglutide and tirzepatide drug products (compounded drugs are mixed or made by a pharmacy rather than an FDA-approved manufacturer). FDA said the labels pictured on the site show "amie," suggesting Amie made the drugs when it did not. FDA also flagged website claims that the compounded products contain the same active ingredients as Ozempic, Mounjaro and Wegovy, and that "All our treatments use FDA-approved active ingredients."
What FDA found
The labels shown on the website display "amie" as if Amie were the maker of the drugs, but Amie is not the compounder.
21 C.F.R. § 201.1(h)(2); FD&C Act § 502(a) [21 U.S.C. § 352(a)]The website says its compounded semaglutide and tirzepatide contain the same active ingredients as Ozempic, Mounjaro and Wegovy, which misleads buyers about how these products compare.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website says "All our treatments use FDA-approved active ingredients," which implies the compounded drugs themselves are FDA-approved when compounded drugs are not.
FD&C Act §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Selling these misbranded drugs across state lines is a prohibited act.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells Amie to send a written response to its Office of Compounding Quality and Compliance within 15 business days, listing the entities that make the compounded drugs, providing sample labeling, and fixing or removing the misleading website claims.
Who should pay attention
- telehealth companies and online pharmacies selling compounded GLP-1 drugs
- marketing and compliance staff who write website claims for prescription products
- compounders whose drugs are relabeled and sold by telehealth partners
This is a summary. Read the original letter on fda.gov.